---
aliases: [TEM, Tempus AI]
---
#actor #healthcare #ai #usa #public

**Tempus** — AI precision medicine leader. $1.27B revenue (2025E, +80% YoY). Stock +70% in 2025. 95% of top 20 pharma partners.

---

## Why Tempus matters

| Metric | Value |
|--------|-------|
| Ticker | TEM ([[Nasdaq]]) |
| 2025E revenue | **$1.27B** (+80% YoY) |
| Q3 2025 revenue | $334M (+85% YoY) |
| Market cap | ~$10B+ |
| Data library | **200M+** clinical records |
| Stock 2025 | **+70%** (hit $100+ high) |

---

## 2025 financial performance

| Quarter | Revenue | Growth |
|---------|---------|--------|
| Q1 2025 | $256M | +75% YoY |
| Q2 2025 | $315M | +90% YoY |
| Q3 2025 | $334M | +85% YoY |
| **FY25E** | **$1.27B** | **+80% YoY** |

**Profitability:** Q3 Adjusted EBITDA $1.5M (vs -$22M prior year). FY25 slightly positive EBITDA expected.

---

## Business segments

| Segment | Description |
|---------|-------------|
| **[[Genomics]]** | xT, xF, xG testing, MRD assays |
| **Data/Services** | Pharma licensing, analytics |
| **Apps** | Olivia consumer, David clinical AI |

---

## AI platforms

| Platform | Function |
|----------|----------|
| **Lens** | Clinical decision support |
| **Next** | Drug discovery acceleration |
| **David** | Generative AI clinical co-pilot (EHR integrated) |
| **Olivia** | [[Consumer]] health app ($12/month) |

**David:** First EHR integration at Northwestern Medicine.

---

## Pharma partnerships

**95% of top 20 pharma oncology companies partner with Tempus.**

| Partner | Deal | Value |
|---------|------|-------|
| **[[AstraZeneca]] + Pathos** | Cancer AI model | $200M (3 years) |
| **GSK** | Data platform expansion | $70M upfront |
| [[Pfizer]] | Oncology drug discovery | Multi-year |
| Boehringer Ingelheim | Cancer pipeline | May 2025 |
| [[Illumina]] | NGS evidence generation | Collaboration |

---

## Recent acquisitions

| [[Target]] | Focus |
|--------|-------|
| **Paige** | AI digital pathology |
| **Ambry Genetics** | Genetic testing scale |

---

## Olivia consumer app

| Feature | Detail |
|---------|--------|
| Price | $12/month |
| EHR integration | 1,000+ health systems |
| Device sync | Health trackers |
| AI insights | Personalized recommendations |
| Clinical trials | clinicaltrials.gov connection |

---

## JPM [[Healthcare]] 2026

| Detail | Value |
|--------|-------|
| Date | Jan 12, 2026 |
| Time | 1:30-2:10 PM PT |
| Presenter | Eric Lefkofsky (CEO) |
| Format | Presentation + Q&A |

---

## Investment case

**Bull:**
- 80% revenue growth at scale
- Near profitability (EBITDA positive FY25)
- 95% top pharma penetration
- Data moat (200M+ records)
- AI platform expansion (Olivia, David)

**Bear:**
- Still unprofitable (net loss)
- Competition (Foundation Medicine/[[Roche]])
- Reimbursement uncertainty
- Valuation premium
- [[Healthcare]] AI adoption pace

---

## Quick stats

| Metric | Value |
|--------|-------|
| Ticker | TEM |
| Exchange | [[Nasdaq]] |
| Revenue | ~$1.27B (2025E) |
| Focus | AI precision medicine |

---

## Related

- [[Biopharma]] — sector
- [[Pfizer]] — pharma partner
- [[JPM Healthcare Conference 2026]] — presenting

---

## Sources

- [Tempus Q3 2025 results](https://investors.tempus.com/news-releases/news-release-details/tempus-reports-third-quarter-2025-results)
- [[[AstraZeneca]] $200M deal](https://www.pharmaceutical-technology.com/news/astrazeneca-enters-200m-ai-cancer-pact-with-tempus-and-pathos/)

*Updated 2026-01-09*
